Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M
Department of Pharmacy, Kumamoto University Hospital, Japan.
Biol Pharm Bull. 2000 Dec;23(12):1528-31. doi: 10.1248/bpb.23.1528.
The objective of this study was to determine whether human immunodeficiency virus (HIV) protease inhibitors (saquinavir, ritonavir and nelfinavir) interact with other HIV protease inhibitors and/or HIV reverse transcriptase inhibitors (zidovudine, didanosine, lamivudine, zalcitabine and sanilvudine). We measured transport of nelfinavir, an HIV protease inhibitor which is known as a substrate for the multidrug resistance transporter P-glycoprotein (P-gp), in an epithelial monolayer model and Ki for P-gp of some drugs by a calcein flux assay. Transport in a basal to apical direction was 2-fold greater than apical to basal flux for nelfinavir, Ki for P-gp of a potent P-gp inhibitor cyclosporin A was 1.09 microM and those of ritonavir and nelfinavir were 111 microM and 28.6 microM, whereas all HIV reverse transcriptase inhibitors gave high K1 values. These data show that nelfinavir, which is a substrate for P-gp, inhibits a P-gp function as a drug efflux pump and that HIV reverse transcriptase inhibitors do not inhibit P-gp.
本研究的目的是确定人类免疫缺陷病毒(HIV)蛋白酶抑制剂(沙奎那韦、利托那韦和奈非那韦)是否与其他HIV蛋白酶抑制剂和/或HIV逆转录酶抑制剂(齐多夫定、去羟肌苷、拉米夫定、扎西他滨和司他夫定)相互作用。我们在一个上皮单层模型中测量了已知为多药耐药转运蛋白P-糖蛋白(P-gp)底物的HIV蛋白酶抑制剂奈非那韦的转运,并通过钙黄绿素通量测定法测定了一些药物对P-gp的抑制常数(Ki)。奈非那韦从基底到顶端的转运比从顶端到基底的转运大2倍,强效P-gp抑制剂环孢素A对P-gp的Ki为1.09微摩尔,利托那韦和奈非那韦的Ki分别为111微摩尔和28.6微摩尔,而所有HIV逆转录酶抑制剂的Ki值都很高。这些数据表明,作为P-gp底物的奈非那韦抑制了P-gp作为药物外排泵的功能,而HIV逆转录酶抑制剂不抑制P-gp。